Matinas Biopharma Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated November 2, 2020, details the results of the Annual Meeting of Stockholders held on that date for Matinas Biopharma Holdings, Inc. (NYSE American: MTNB). The company is incorporated in Delaware and identifies as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes rather than financial performance.
Material Changes and Voting Results
Stockholders voted on four proposals at the Annual Meeting. The results were as follows:
- Proposal 1 (Election of Directors): All seven nominees were elected to the Board of Directors. Herbert Conrad received the lowest "For" vote count (37,631,103) and the highest "Withheld" count (1,706,069), while Natasha Giordano received the highest "For" vote count (37,936,565). A significant number of shares (102,629,569) were recorded as Broker Non-Votes for all director elections.
- Proposal 2 (Ratification of Auditors): Stockholders approved the appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020. Votes were 141,187,310 For, 434,392 Against, and 345,039 Abstain.
- Proposal 3 (Say-on-Pay): Stockholders approved, on an advisory basis, the compensation of named executive officers. Votes were 35,265,379 For, 2,395,119 Against, and 1,676,674 Abstain. Broker Non-Votes totaled 102,629,569.
- Proposal 4 (Say-on-Pay Frequency): Stockholders approved conducting future advisory votes on executive compensation on an annual (one-year) basis. Votes were 33,236,733 for One Year, 2,275,782 for Two Years, and 3,397,661 for Three Years.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, or contingencies. The document serves solely to report the final tabulation of shareholder votes.
Key Facts for Investor Verification
- Verify the total number of shares outstanding and the percentage of shares represented by the 102,629,569 Broker Non-Votes, which significantly impacted the voting power on director elections and executive compensation.
- Confirm the tenure of the newly elected directors, who will serve until the 2021 annual meeting.
- Review the definitive proxy statement filed on October 1, 2020, for detailed biographies of the directors and the specific compensation packages approved in Proposal 3.
- Note that the company has elected to use the extended transition period for complying with new financial accounting standards as an emerging growth company.